J&J moves Genmab’s Daratumumab into phase III myeloma trial
By Cormac Sheridan
Thursday, March 6, 2014
Janssen Biotech, Inc. is putting its foot on the gas in the development of Genmab A/S’s anti-CD38 multiple myeloma antibody daratumumab. Although it does not yet have any final phase II data in hand, it feels sufficiently emboldened by what it’s seen so far to move the drug into an extensive-phase pivotal program.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.